Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Drop in Short Interest
by Tristan Rich · The Markets DailySonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) saw a significant decline in short interest in July. As of July 31st, there was short interest totaling 8,448 shares, a decline of 83.0% from the July 15th total of 49,784 shares. Based on an average trading volume of 31,236 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the stock are short sold.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded Sonoma Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sonoma Pharmaceuticals has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on Sonoma Pharmaceuticals
Institutional Trading of Sonoma Pharmaceuticals
A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. Institutional investors own 1.95% of the company’s stock.
Sonoma Pharmaceuticals Stock Performance
NASDAQ:SNOA traded down $0.04 during mid-day trading on Friday, reaching $1.30. The stock had a trading volume of 189,730 shares, compared to its average volume of 138,128. The stock has a market capitalization of $6.22 million, a P/E ratio of -1.07 and a beta of 1.28. The firm has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.82. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $5.60.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.32. The firm had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 26.32%.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.
At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.